tiprankstipranks
Acadia Pharmaceuticals price target raised to $28 from $24 at TD Cowen
The Fly

Acadia Pharmaceuticals price target raised to $28 from $24 at TD Cowen

TD Cowen raised the firm’s price target on Acadia Pharmaceuticals to $28 from $24 and keeps an Outperform rating on the shares. The analyst noted they announced FDA approval for Daybue, their synthetic analog of IGF-1 for Rett Syndrome, with a broad, clean label. Daybue is expected to officially launch at end of April with a net annual average price of roughly $375k, along with Acadia Connect, a patient/caregiver/HCP education and financial assistance hub.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ACAD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles